IQV Stock Quote Price and Forecast | CNN

IQV

IQVIA Holdings Inc

Key terms

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Apr 09 7:35am ET Truist Financial Reaffirms Their Buy Rating on IQVIA Holdings (IQV) by TipRanks Apr 08 4:01pm ET Iqvia, Salesforce expand global partnership by TipRanks Mar 29 3:20am ET Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM) by TipRanks Mar 06 8:06am ET Truist Financial Sticks to Their Buy Rating for IQVIA Holdings (IQV) by TipRanks Feb 28 7:55am ET Iqvia price target raised to $300 from $260 at Argus by TipRanks Feb 27 9:11am ET Iqvia price target raised to $297 from $286 at Truist by TipRanks Feb 27 7:41am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), IQVIA Holdings (IQV) and Bausch Health Companies (BHC) by TipRanks Feb 26 7:20am ET Analysts Are Bullish on Top Healthcare Stocks: BeiGene (BGNE), McKesson (MCK) by TipRanks Feb 26 6:18am ET Iqvia initiated with an Outperform at Leerink by TipRanks Feb 23 7:00am ET Iqvia price target raised to $268 from $242 at Mizuho by TipRanks Feb 20 8:41am ET Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), IQVIA Holdings (IQV) and Ascendis Pharma (ASND) by TipRanks Feb 19 5:30am ET Analysts’ Top Healthcare Picks: IQVIA Holdings (IQV), Denali Therapeutics (DNLI) by TipRanks Feb 19 12:51am ET Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), SAGE Therapeutics (SAGE) and IQVIA Holdings (IQV) by TipRanks Feb 15 8:26am ET Iqvia downgraded to Neutral at Guggenheim on valuation by TipRanks Feb 15 8:14am ET Iqvia price target raised to $265 from $255 at Evercore ISI by TipRanks Feb 15 7:56am ET Iqvia price target raised to $270 from $239 at TD Cowen by TipRanks Feb 15 7:53am ET Iqvia price target raised to $300 from $240 at UBS by TipRanks Feb 15 7:37am ET Iqvia price target raised to $290 from $285 at BTIG by TipRanks Feb 15 6:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Feb 15 6:17am ET IQVIA Holdings: A Strong Buy on Robust TAS Growth and RDS Stability by TipRanks Feb 15 6:15am ET Iqvia downgraded to Neutral from Buy at Guggenheim by TipRanks Feb 15 3:10am ET Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Evolent Health (EVH) and InMode (INMD) by TipRanks Feb 14 10:26am ET Iqvia shares up 10% to $236.09 after Q4 earnings beat estimates by TipRanks Feb 14 10:25am ET Iqvia sees FY24 adjusted EPS $10.95-$11.25, consensus $11.07 by TipRanks Feb 14 10:24am ET Iqvia reports Q4 adjusted EPS $2.84, consensus $2.82 by TipRanks Feb 14 9:55am ET Early notable gainers among liquid option names on February 14th by TipRanks Feb 13 8:25pm ET Notable companies reporting before tomorrow’s open by TipRanks Feb 05 8:45pm ET AbbVie price target raised to $172 from $165 at UBS by TipRanks Jan 24 7:19am ET Iqvia price target raised to $260 from $215 at Barclays by TipRanks Jan 18 6:24am ET Iqvia price target raised to $226 from $221 at Baird by TipRanks

Mar 17 5:50am ET Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? by Motley Fool

No recent press releases are available for IQV

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Donald Trump might no longer own a majority of TMTG after a new public share offering.

Joe Raedle/Getty Images

Trump stock tanks after announcing massive share sale

1040 US Individual Income Tax Return Form

Nora Carol Photography/Moment RF/Getty Images

Three ways investors can minimize their tax payments

People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.

Spencer Platt/Getty Images

Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel

JPMorgan beat earnings expectations this Friday, unofficially kicking off the first quarter earnings season.

Win McNamee/Getty Images

Jamie Dimon says chance of a bad economy is ‘higher than other people think’